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 Congenital hereditary endothelial dystrophy (CHED) is
a rare corneal genetic disorder. It can be inherited as an auto-
somal dominant (CHED1, OMIM 121700) or autosomal re-
cessive (CHED2, OMIM 217700) trait in families. It is char-
acterized by diffuse bilateral corneal clouding with no other
cause and nystagmus [1]. CHED2 manifests at birth or within
the neonatal period and is generally more severe than CHED1,
which usually develops later in childhood [1]. CHED1 has
been mapped to the pericentromeric region of chromosome
20p11.2-q11.2 [2]. Homozygosity mapping has been imple-
mented to map CHED2 to a different region on chromosome
20p13-p12 in an 8 cM region between D20S113 and D20S882
markers in a large consanguineous Irish family [1]. Mohamed
et al. [3] subsequently confirmed the linkage of CHED2 in
another family. Recently, Vithana et al. [4] found mutations in
the SLC4A11 gene (also known as BTR1, Bicarbonate Trans-
porter-Related protein-1) in 10 CHED2 families from
Myanmar, Pakistan, and India. Subsequently, Jiao et al. [5]
found mutations in 12/16 Indian families. The SLC4A11 gene
has 19 exons, the first and parts of exons 2 and 19 being
noncoding [6]. The gene transcribes to an mRNA (GenBank
NM_032034) of 3,138 bases, which codes for a protein of
891 amino acids with a calculated molecular mass of 100 kDa
[6]. It contains 14 transmembrane domains (TMDs) and intra-
cellular NH2- and COOH-termini [6]. It also contains mul-
tiple intracellular phosphorylation sites and two extracellular
N-glycosylation sites [6]. The gene is expressed in several
organs and tissues including eye, blood, lung, ovary, colon,
mouth, embryonic tissue, pancreas, kidney, skin, cranial nerve,
ascites, prostate, and brain (NCBI Unigene expression pro-
file). Sodium bicarbonate transporter-like solute carrier fam-
ily 4 member 11 (SLC4A11) is a member of the SLC4 family
of bicarbonate transporters [7]. In humans, SLC4 and SLC26
families are the main bicarbonate transporters [7]. SLC4A11
is a Na/borate cotransporter and stimulates cell growth and
proliferation by increasing intracellular borate and activating
the MAPK pathway [8,9]. Here we report genetic analysis of
two CHED2 families ascertained from a south Indian state of
Karnataka.
METHODS
Families:  We have ascertained two multigenerational fami-
lies (Figure 1 and Figure 2) with autosomal recessive CHED2
from a south Indian state of Karnataka. Family 1 has 17 living
individuals including three affected ones. Family 2 has 18 liv-
ing individuals including five affected ones. All family mem-
bers were examined in detail. All affected individuals in both
families had congenital bilateral cloudy cornea. In family 1,
individuals III-3 and III-5 also had secondary spheroidal de-
generation of corneal epithelium with nystagmus. Individual
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family. This mutation is predicted to truncate the protein with a lack of all 14 transmembrane domains. DNA sequence
analysis of the second family showed a novel in-frame deletion mutation c.2014_2016delTTC or 2017_2019delTTC
which will lead to the loss of a phenylalanine residue at position 672 or 673 (F672del or F673del). The mutant protein is
expected to lack a conserved phenylalanine residue in transmembrane domain number 8.
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39V-1 had only nystagmus. All affected individuals from family
2 also had secondary spheroidal degeneration of corneal epi-
thelium with nystagmus. No difference was found in clinical
symptoms between families 1 and 2. Informed consent was
obtained from each family. Our research followed the guide-
lines of the Indian Council of Medical Research, New Delhi.
Genetic analysis:  Peripheral blood samples were drawn
from individuals in both families into Vacutainer™ EDTA
tubes (Beckton-Dickinson, Franklin Lakes, NJ). Peripheral
blood samples from 50 ethnically matched and unrelated nor-
mal individuals (controls) were also collected. These individu-
als did not have any signs or symptoms of CHED or any other
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Figure 1. Haplotype analysis of family 1.  Haplotype analysis was carried out using 11 microsatellite markers. Disease haplotype is boxed.
Note the affected individuals (III-3, III-5, and V-1) are homozygous for the disease haplotype. Individuals II-2, III-6, IV-6, IV-7, IV-8, and V-
2 are heterozygous for the disease haplotype and are therefore carriers for the mutation. Empty squares and circles represent normal males and
females, respectively. Filled squares and circles represent affected individuals. Affected individuals III-3, III-5, and V-1 are 42, 50, and 6 years
old, respectively.
40eye disease. Genomic DNA samples were isolated from pe-
ripheral blood samples using a Wizard™ genomic DNA ex-
traction kit (Promega, Madison, WI). To determine if CHED
in these families is due to mutations in the SLC4A11 gene lo-
cated on chromosome 20p13-p12, we selected 11 microsatellite
markers (Table 1) from the CHED2 candidate region [1] and
used them to genotype the families. The genotyping was car-
ried out as described in Venkatesh et al. [10]. The haplotypes
were constructed by hand. For mutation analysis, we designed
primer sets for the entire coding region of the SLC4A11 gene
including intron-exon junctions (Table 2). Mutations in this
gene were identified by sequencing the PCR products from
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Figure 2. Haplotype analysis of family 2.  Haplotype analysis was carried out using 11 microsatellite markers. Disease haplotype is boxed.
Note the affected individuals (viz., III-1, III-3, III-5, IV-3, and IV-6) are homozygous for the disease haplotype. Whereas individuals II-3, IV-
1, IV-5, IV-7, IV-8, V-3, and V-4 are heterozygous for the disease haplotype and are therefore carriers for the mutation. Empty squares and
circles represent normal males and females, respectively. Filled squares and circles represent affected individuals. Affected individuals III-1,
III-3, III-5, IV-3, and IV-6 are 70, 65, 45, 30, and 30 years old, respectively.
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TABLE 1. MICROSATELLITE MARKERS FROM THE CANDIDATE REGION
OF THE SLC4A11 GENE
                   Genetic
                   distance
Number   Markers     (cM)
------   -------   --------
1        D20S199     6.25
2        D20S906     7.61
3        D20S842     8.97
4        D20S181     9.53
5        D20S193     9.53
6        D20S473     9.53
7        D20S889    11.20
8        D20S116    11.20
9        D20S867    12.12
10       D20S895    13.98
11       D20S849    13.98
Genetic distance was obtained from the Marshfield Medical Research
Foundation web site. Marker order was established using the sequence
map from the UCSC Genome Bioinformatics site. According to this
site, the order of markers is as follows: D20S199-D20S906-D20S842-
D20S181-D20S193-D20S473-D20S867-D20S889-D20S116-
D20S895-D20S849.
TABLE 2. PRIMERS USED FOR THE MUTATION ANALYSIS OF THE
SLC4A11 GENE
                                        Annealing    Amplicon
                                       temperature     size
Exon         Sequence (5'-3')             (°C)         (bp)
----   -----------------------------   -----------   --------
2      F: ATTAAGGCTGGCTTCCCCTGCTATG        67          303
       R: CCCTGGAGGCTTTTGCCCGACAAG
3&4    F: CCTTCCTGTGTGTGGCACTTTAACAG       67          439
       R: ATCACCTCAGCCCCCAGGTAGAGG
5      F: ACCAGGCAGTGACAGCATCTCATAC        67          354
       R: GGGTGGTGGGTCAACAGCCCCTC
6      F: GGGGGCGTTGGGAGGGGCTGTTGA         67          201
       R: AGGGGACATGGGACACCCAGTTCCAC
7      F: GTCGGGGAGCCCCAGCTCCCTGG          67          254
       R: GGACCCCAAGCAGAGGGCGGGTAA
8      F: CCCGGGCAGGGCCTCCTCTGTTTC         67          328
       R: GACAGAGCGCCTGTTAGCCCTGTCC
9&10   F: TCGGCGGGGGCATGGGCCGGACA          67          419
       R: AGCCCAGGGCCCAGCCCAGCATAC
11     F: TATGCTGGGCTGGGCCCTGGGCTG         67          444
       R: GGGCTGAACCAGATCCCAAGCCTTGA
12     F: GGGGCTCAGGGAGGCCTCCCCCA          67          210
       R: AGTGCAGAACCTCCCATCTCGGCTG
13     F: TCCAGGGCCTCCCCCTGCCACAC          67          382
       R: GGGACAGCAGGTGCATGAGCACAGC
14     F: GAGGGGAGGGGCCGCATGGGTCAA         67          239
       R: AGTAGGGGACAGGCTACTGCTATGCC
15     F: GGCGGTGGGTGACGTGGGGTAGC          67          304
       R: CTCGTGGACAGAGCCCCACAGCAGA
16     F: CACCGGAGAACAGGTGTGGAGGGTG        65          325
       R: GGCCAGAGGCTCCCCACTCCTCAG
17     F: GGAGGAGTGAGGCCCTGTGGACAGG        67          340
       R: TGTGGGCGGCAGGGACCGGGTGTG
18     F: GGCGTGGGTGGGGACACAGCCCCA         67          289
       R: CAGCCCGCCCATTCTCCACACCTAGA
19     F: TGGGATGGGTGTCCACTGCCTTCTC        67          199
       R: GCTCCAGAGCCAGCCTGGGAGGAC
Primers were designed using genomic DNA and mRNA (GenBank
NM_032034) sequences from the UCSC Genome Bioinformatics site.
This mRNA does not have exon 1 sequences. Exon 1 was not ana-
lyzed as it is a part of the 5'-UTR.
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Figure 3. Mutation analysis of the SLC4A11 gene in family 1.  A: Sequencing chromatogram of the exon 8 PCR product from the affected
individual V-1. Normal DNA sequence is written on the top of the chromatogram. The deleted nucleotide residues “GAGA” is underlined in
the normal sequence. Note deletion of GAGA and insertion of CCT (underlined) in the chromatogram. B: Agarose gel electrophoresis of PCR
products from all individuals using wild-type (upper panel) and mutant allele-specific primer sets (lower panel). Note all normal individuals
had bands in the upper panel as expected. All heterozygotes and patients had bands in the lower panel as expected. Lanes M and B stand for
100 bp marker and no template PCR, respectively. Individuals noted on top of the gel pictures are as in Figure 1. An asterisk marks the primer-
dimer band.one patient from each family on an ABI Prism A310 auto-
mated sequencer (PE Biosystems, Foster City, CA) as sug-
gested by the vendor. PCR was carried out in a total volume
of 25 µl containing 50-100 ng of genomic DNA, 1.5 mM
MgCl2, 200 µM of each dNTP, 1X buffer and 1 unit of Taq
DNA polymerase (Sigma-Aldrich Chemicals Pvt. Ltd., Ban-
galore, India) using a PTC-100 thermocycler (MJ Research
Inc., Waltham, MA). PCR conditions were as follows: An ini-
tial denaturation at 95 °C for 2 min was followed by 35 cycles
of denaturation at 95 °C for 30 s, annealing at 65 or 67 °C for
30 s, extension at 72 °C for 1 min, with a final extension at 72
°C for 5 min. Prior to sequencing, PCR products were puri-
fied using the GenEluteTM gel extraction kit (Sigma-Aldrich
Chemicals). A mutation was detected in family 1, so all mem-
bers in this family were examined for the presence of the mu-
tant and wild-type alleles by allele-specific PCR. Allele-spe-
cific PCR was carried out using a common reverse primer
CHED8R (5'-ACC TCT GGG TGT CTG TGG GCA GGG A-
3') and wild-type allele-specific forward primer CHED8WF
(5'-GCC TTC CGC CAG AAG CTC CTG GAG A-3') or mu-
tant allele-specific forward primer CHED8MF (5'-GCC TTC
CGC CAG AAG CTC CTG CCT C-3'). CHED8WF-CHED8R
and CHED8MF-CHED8R primer sets were used to amplify
161 and 160 bp amplicons, respectively with an annealing tem-
perature at 62 °C. Allele-specific PCR was also used to deter-
mine if the mutation in family 1 was not present in 50 ethni-
cally matched normal controls. Similarly, after a mutation was
detected in family 2, the rest of the family members and 50
controls were examined for the presence of the mutant and
wild-type alleles by allele-specific PCR. Allele-specific PCR
was carried out using a common reverse primer CHED15R
(5'-AGG AGG TCC CAG TGG TAG GCA GTG-3') and wild-
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Figure 4. Mutation analysis of the SLC4A11 gene in family 2.  A: Sequencing chromatogram of the exon 15 PCR product from the affected
individual IV-3. Normal DNA sequence is written on the top of the chromatogram. The tandem repeats of two “TTC” are underlined. Note
only one TTC (underlined) in the chromatogram. B: Agarose gel electrophoresis of PCR products from all individuals using wild-type (upper
panel) and mutant allele-specific primer sets (lower panel). All normal individuals have bands in the upper panel as expected. All heterozy-
gotes and patients have bands in the lower panel as expected. Lanes M and B stand for 100 bp marker and no template PCR, respectively.
Individuals noted on top of the gel pictures are as in Figure 2. An asterisk marks the primer-dimer band.type allele-specific forward primer CHED15WF (5'-CTT CCT
GCT GTC CAT GCT CTT CTT CA-3') or mutant allele-spe-
cific forward primer CHED15MF (5'-GGC TTC CTG CTG
TCC ATG CTC TTC A-3'). CHED15WF-CHED15R and
CHED15MF-CHED15R primer sets amplified 192 and 189
bp amplicons, respectively with an annealing temperature at
62 °C. Mutation nomenclature is according to den Dunnen
and Antonarakis [11].
RESULTS & DISCUSSION
 Visual inspection of both pedigrees (Figure 1 and Figure 2)
suggested that CHED is segregating as an autosomal reces-
sive trait in both families. Haplotype analysis using 11
microsatellite markers selected from the candidate region of
the CHED2 locus showed that all the affected individuals in
family 1 were homozygous for D20S906, D20S842, D20S181,
D20S193, D20S473, D20S867, D20S889, and D20S116. Het-
erozygosities at D20S199 and D20S895 in affected individual
V-1 placed the CHED2 locus between D20S199 (6.25 cM)
and D20S895 (13.98 cM) markers in a genetic distance of 7.73
cM. A disease haplotype 2-11-4-2-3-3-1-2 at marker loci
D20S906-D20842-D20S181-D20S193-D20S473-D20S867-
D20S889-D20S116 cosegregated with the disease in family 1
(Figure 1). Haplotype analysis using the same set of markers
showed that all affected individuals in family 2 were homozy-
gous for all 11 markers (Figure 2). A different disease haplo-
type 10-2-6-4-2-4-4-7-1-5-6 co-segregated with the disease
at marker loci D20S199-D20S906-D20842-D20S181-
D20S193-D20S473-D20S867-D20S889-D20S116-D20S895-
D20S849 in family 2 (Figure 2). This suggested that the CHED
phenotype in both families is linked to the CHED2 locus, and
different mutations are responsible for the disease phenotype
in both families. Recently, Vithana et al. [4] identified the gene
responsible for CHED2; it lies between D20S181 and
D20S193. Therefore, we directed our efforts in the mutation
analysis of the SLC4A11 gene in both families.
 DNA sequence analysis of the affected individual V-1
from family 1 showed a deletion of four nucleotide residues
GAGA from nucleotide positions 859 to 862 in exon 8, which
was replaced by an insertion of three nucleotide residues CCT
in a homozygous state (Figure 3A), resulting in an indel mu-
tation c.859_862delGAGAinsCCT. As expected from the hap-
lotype data (Figure 1), allele-specific PCR showed that all
patients and heterozygotes had the mutant allele (Figure 3B).
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TABLE 3. SUMMARY OF MUTATIONS DETECTED SO FAR IN THE SLC4A11 GENE IN CHED2 FAMILIES
                                   Nature
                         Exon/       of                                Ethnic origin
       Mutation          intron   mutation    Effect on protein         of families        Reference
----------------------   ------   --------   --------------------   --------------------   ---------
g.2943delTTinsA             2       Indel    Truncation of          1 Indian family           [5]
(R82RfsX33)                                  protein and addition
                                             of novel amino acids
c.353_356delAGAA            4     Deletion   Truncation of          1 Indian family           [4]
                                             protein
c.859-862delGAGAinsCCT      8       Indel    Truncation of          1 Indian family         Present
(E287fsX21)                                  protein and addition                           study
                                             of novel amino
                                             acids, absence of
                                             all TMDs
c.1391G>A (G464D)          11     Missense   Conformation change    3 Pakistani families      [4]
c.1466C>T (S489L)          12     Missense   Conformation change    1 Pakistani family        [4]
g.8118delCT                13     Deletion   Truncation of          1 Indian family           [5]
(H568HfsX177)                                protein and addition
                                             of novel amino acids
c.1813C>T (R605X)          14     Nonsense   Truncation of          3 Indian families       [4],[5]
                                             protein
g.8379G>T (E632X)          14     Nonsense   Truncation of          1 Indian family           [5]
                                             protein
IVS15-6_-16delins          15       Indel    Inactivation of an     1 Indian family           [4]
GGCCGGCCGG                                   acceptor splice site
c.2014_2016delTTC or       15     In-frame   Disruption of TMD      1 Indian family         Present
c.2017_2019delTTC                 deletion   number 8                                       study
(F672del or F673del)
c.2264G>A (R755Q)          17     Missense   Conformation change    2 Indian and           [4],[5]
                                                                    1 Myanmar families
g.9191G>A (R804H)          17     Missense   Conformation change    1 Indian family           [5]
g.9200delTinsGG            17      Indel     Truncation of          1 Indian family           [5]
(L807RfsX71)                                 protein and addition
                                             of novel amino acids
g.9361C>T (T833M)          18     Missense   Conformation change    2 Indian families         [5]
c.2605C>T (R869C)          18     Missense   Conformation change    1 Indian families         [4]
g.9469G>A (R869H)          18     Missense   Conformation change    2 Indian families         [5]
A total of 16 SLC4A11 mutations have been detected so far in 24 CHED2 families from Myanmar, Pakistan, and India.
44The wild-type allele was present in heterozygotes and normal
individuals (Figure 3B). This mutation was not present in 100
normal control chromosomes (data not shown). This muta-
tion is predicted to truncate SLC4A11 protein with the intro-
duction of 21 novel amino acid residues beginning from amino
acid position 287 (E287fsX21). The mutant protein is predicted
to lack all 14 transmembrane domains. This suggests that the
disease phenotype could be due to the lack of the mutant pro-
tein in the membrane.
DNA sequence analysis of the affected individual IV-3
from family 2 revealed in-frame deletion of three nucleotide
residues TTC from nucleotide positions 2014 to 2016 or 2017
to 2019 as there are two tandem TTC residues in exon 15 in a
homozygous state, resulting in the mutation
c.2014_2016delTTC or c.2017_2019delTTC (Figure 4A). As
expected from the haplotype data (Figure 2), allele-specific
PCR showed that all patients and heterozygotes had the mu-
tant allele (Figure 4B). The wild-type allele was present in
heterozygotes and normal individuals (Figure 4B). This mu-
tation was not present in 100 normal control chromosomes
(data not shown). This mutation will lead to the loss of a phe-
nylalanine residue at position 672 or 673 (F672del or F673del).
Phenylalanine residues at position 672 and 673 lie in the trans-
membrane domain number 8 of the SLC4A11 protein [6]. This
suggests that the deletion of phenylalanine at either position
may disrupt the localization or proper assembly of this pro-
tein in the membrane. It is possible that the true functional
polymorphism (mutation) may not be this deletion and rather
another polymorphism in LD (linkage disequilibrium) with
the deletion. However, this possibility is unlikely as no other
mutation has been detected in the entire coding region and at
intron-exon junctions of this gene in the affected individual
IV-3. Moreover, the phenylalanine residue at position 673 is
conserved in members of the human bicarbonate transporter
superfamily such as AE4, NBC1, NDCBE1, AE1, and CeBTR
[6]. Interestingly, in-frame deletion of a phenylalanine resi-
due at position 508 (deltaF508) has been reported in another
transmembrane protein CFTR [12]. However, the deletion of
phenylalanine residue is not located in TMD and occurs in the
nucleotide ATP-binding fold 1 (NBF1) region of CFTR [12].
Vithana et al. [4] reported a total of seven mutations in
this gene, which include four missense, one nonsense, one
deletion, and one acceptor site splice mutations in 10 CHED2
families from Myanmar, Pakistan, and India (Table 3). Jiao et
al. [5] carried out mutation analysis of the SLC4A11 gene in
16 Indian families and found nine different mutations in 12
families; four missense, two nonsense, one deletion and two
indel mutations. Two mutations, R605X and R755Q, were
identified by both groups (Table 3). When data from both
groups and the present study are considered together, the total
number of mutations in the SLC4A11 gene reaches 16 which
includes seven missense, two nonsense, three deletions, and
four indel mutations (Table 3).
In summary, we report two novel mutations
(c.859_862delGAGAinsCCT/E287fsX21 and
c.2014_2016delTTC or c.2017_2019delTTC/F672del or
F673del) in the SLC4A11 gene in two Indian CHED2 fami-
lies. Of 24 CHED2 families with mutations in SLC4A11, 23
are from India (Table 3). It will be interesting to see the range
and types of mutations in this gene in families from other popu-
lations. We suggest that the disease phenotype in both fami-
lies could be due either to the absence of the protein in the
membrane or improper membrane localization of the protein.
The present information will be useful to provide rapid prena-
tal diagnosis and genetic counseling to families and their rela-
tives using an allele-specific PCR method developed during
our study.
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